The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
Neurology
AAN 2020 DAILY REPORT – WEDNESDAY, APRIL 29 EDITION
April 29, 2020The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
AAN 2020 DAILY REPORT – TUESDAY, APRIL 28 EDITION
April 28, 2020The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
Siponimod – new data in SPMS
April 23, 2020Click here to take the SPMS survey
Siponimod, the selective sphingosine-1-phosphate (S1P) receptor modulator (S1P1,5), produces a sustained reduction in worsening disability for up to five years in patients with secondary-progressive MS (SPMS), according to data submitted to the American Academy of Neurology annual meeting (Kappos et al. AAN 2020; abstract S40.003).
FDA approves ozanimod in MS
April 16, 2020The U.S. Food and Drug Administration has approved ozanimod (Zeposia) for the treatment of relapsing forms of MS, including clinically isolated syndrome (CIS), RRMS and active SPMS. The drug was developed by Receptos, then acquired by Celgene before Celgene was acquired in turn by Bristol-Myers Squibb. Ozanimod was submitted for review by Health Canada in December 2019. Read More